These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22652186)

  • 41. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
    Lagalla G; Millevolte M; Capecci M; Provinciali L; Ceravolo MG
    Mov Disord; 2006 May; 21(5):704-7. PubMed ID: 16440332
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Botulinum toxin use in neuro-rehabilitation to treat obstetrical plexus palsy and sialorrhea following neurological diseases: a review.
    Intiso D; Basciani M
    NeuroRehabilitation; 2012; 31(2):117-29. PubMed ID: 22951705
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment of Sialorrhea with Botulinum Neurotoxin Type A - Consensus Practice Recommendations for Children and Adults].
    Jost WH; Bäumer T; Bevot A; Birkmann U; Buhmann C; Grosheva M; Guntinas-Lichius O; Mlynczak U; Paus S; Pflug C; Schröder S; Steffen A; Wilken B; Berweck S
    Fortschr Neurol Psychiatr; 2022 May; 90(5):212-221. PubMed ID: 35453158
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Botulinium toxin in ENT].
    Klap P
    Ann Otolaryngol Chir Cervicofac; 2006 Dec; 123(6):306-11. PubMed ID: 17202988
    [No Abstract]   [Full Text] [Related]  

  • 45. [Applications of botulinum toxin in Neurology].
    Garcia-Ruiz PJ
    Med Clin (Barc); 2013 Jul; 141(1):33-6. PubMed ID: 23434466
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does motor performance matter in botulinum toxin efficacy for drooling?
    Erasmus CE; Scheffer AR; van Hulst K; van Limbeek J; van den Hoogen FJ; Rotteveel JJ; Jongerius PH
    Pediatr Neurol; 2011 Aug; 45(2):95-9. PubMed ID: 21763949
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Botulinum toxin A after microvascular ALT flap in a patient with (corrected) squamous cell carcinoma of the tongue].
    Ihler F; Laskawi R; Matthias C; Rustenbeck HH; Canis M
    HNO; 2012 Jun; 60(6):524-7. PubMed ID: 22534678
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia.
    Pelletier F; Parratte B; Penz S; Moreno JP; Aubin F; Humbert P
    Br J Dermatol; 2011 Mar; 164(3):617-22. PubMed ID: 21275944
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multidisciplinary management of sialorrhea in children.
    Daniel SJ
    Laryngoscope; 2012 Dec; 122 Suppl 4():S67-8. PubMed ID: 23254608
    [No Abstract]   [Full Text] [Related]  

  • 50. Botulinum toxin for urogenital conditions.
    Eccleston KJ; Woolley PD
    Int J STD AIDS; 2008 Dec; 19(12):797-9. PubMed ID: 19050206
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dysphagia as a complication of botulinum toxin injection to treat drooling.
    Tighe D; Gok G; Moody A; Howlett D
    Br J Oral Maxillofac Surg; 2014 Sep; 52(7):673; discussion 673-4. PubMed ID: 24845119
    [No Abstract]   [Full Text] [Related]  

  • 52. Application of botulinum toxin to clinical therapy: advances and cautions.
    Levy NS; Lowenthal DT
    Am J Ther; 2012 Jul; 19(4):281-6. PubMed ID: 22481607
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Botulinum toxin for lower lid entropion correction.
    Deka A; Saikia SP
    Orbit; 2011 Jan; 30(1):40-2. PubMed ID: 21281080
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment with botulinum toxin in children with chronic anal fissure.
    Husberg B; Malmborg P; Strigård K
    Eur J Pediatr Surg; 2009 Oct; 19(5):290-2. PubMed ID: 19746337
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders.
    Porta M; Gamba M; Bertacchi G; Vaj P
    J Neurol Neurosurg Psychiatry; 2001 Apr; 70(4):538-40. PubMed ID: 11254784
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of botulinum toxin type a in the bladder wall of children with neurogenic bladder dysfunction: a comparison of histological features before and after injections.
    Pascali MP; Mosiello G; Boldrini R; Salsano ML; Castelli E; De Gennaro M
    J Urol; 2011 Jun; 185(6 Suppl):2552-7. PubMed ID: 21527192
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Botulinum toxin type A in the management of a neuropathic foot ulcer.
    Alsharqi A; Curley R; Winhoven S
    Clin Exp Dermatol; 2011 Dec; 36(8):915-6. PubMed ID: 21623883
    [No Abstract]   [Full Text] [Related]  

  • 58. Patient benefit from treatment with botulinum neurotoxin A for functional indications in otorhinolaryngology.
    Braun T; Gürkov R; Hempel JM; Berghaus A; Krause E
    Eur Arch Otorhinolaryngol; 2010 Dec; 267(12):1963-7. PubMed ID: 20563590
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sialorrhea - therapeutic drug options.
    Tscheng DZ
    Ann Pharmacother; 2002 Nov; 36(11):1785-90. PubMed ID: 12398577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A systematic review of the perspectives of botulinum toxin use on the quality of life of neurological patients with drooling.
    Silva MA; da Silveira MMF; Pedrosa BRV; Dos Santos RTNT; de Farias ZBBM; Sobral APV
    Clin Oral Investig; 2024 May; 28(6):322. PubMed ID: 38758415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.